États-Unis · Magazines éco · Markets Insider (Business Insider)

uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntingtonâs Disease

Publié par Markets Insider (Business Insider) · États-Unis il y a 7 h

~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the worldâs first disease-modifying...

Lire l'article complet sur Markets Insider (Business Insider) Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (markets.businessinsider.com)

À lire aussi

Martha Stewart Promoted Her QVC Line With a Homelessness Costume. Critics Called It ‘Ridiculously Offensive’

10 highest mountains in the world, from Everest at 8,849 meters to Annapurna I

The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash

Meta’s web crawlers are making life hell for owners of small business websites

Hackers Stole $6.3 Billion From Binance in the Biggest Crypto Heist Ever — Will Users Get Their Money Back?

Did I Miss My Chance to Do a Roth Conversion?